Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

Completed · Phase 1

Conditions studied: Cancer

In brief

This phase I study aims to assess the safety and tolerability of a new drug - PG-11047 - and to establish what happens to the drug once inside the body. An escalating dose of PG-11047 will be investigated in this study and the maximum tolerated dose of the drug will be established.

Key facts

Study ID

NCT00705653

Run by

Progen Pharmaceuticals

People needed

46

Starts

2005-03-01

Expected to finish

2009-08-01

Last updated by the study team

2012-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• non-hematological malignancy where standard therapeutic measures do not exist or no longer effective.
• ECOG - 0-2.
• Life expectancy > 3 months.

You may not qualify if…

• chemotherapy or radiotherapy within 4 weeks prior to entering the study.
• previous high-dose chemotherapy with autologous allogeneic hematopoietic stem cell transplantation.
• primary brain tumors or active brain metastases
• history of significant or symptomatic cardiac arrhythmia, prior myocardial infarction or evidence of a current significant ventricular conduction abnormality

Where it is running

• University of Chicago, Cancer Research Centre — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.